Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
esomeprazole + bismuth subcitrate + amoxicillin + metronidazole
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a four-drug combination therapy consisting of esomeprazole (a proton pump inhibitor), bismuth subcitrate (a gastrointestinal protectant with antimicrobial activity), amoxicillin (a beta-lactam antibiotic), and metronidazole (a nitroimidazole antibiotic). The regimen is used primarily for the eradication of Helicobacter pylori infection, especially in cases where resistance or intolerance to other regimens exists. Esomeprazole reduces gastric acid secretion, enhancing the effectiveness of antibiotics against H. pylori. Bismuth subcitrate provides direct antimicrobial action and mucosal protection. Amoxicillin disrupts bacterial cell wall synthesis, while metronidazole causes DNA strand breakage in anaerobic bacteria like H. pylori[3][4][6]. This quadruple therapy is an alternative to classic bismuth-based regimens that use tetracycline instead of amoxicillin.
- Brand names
- None found specific to this exact combination
- Other names
- None found specific to this exact combination
02
Targets
PBP (Penicillin-binding protein family)ATP4A (Potassium–transporting ATPase alpha chain 1)Neuraminidase
Beyond the preview
Go deeper on esomeprazole + bismuth subcitrate + amoxicillin + metronidazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on esomeprazole + bismuth subcitrate + amoxicillin + metronidazole.